NASDAQ: CMMB
Chemomab Therapeutics Ltd Stock Ownership - Who owns Chemomab Therapeutics?

Insider buying vs selling

Have Chemomab Therapeutics Ltd insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Neil Harris CohenDirector2026-08-281,000$2.80
$2.80kSell
Neil Harris CohenDirector2026-08-271,304$2.85
$3.72kSell
George Adi MorChief Executive Officer2026-05-294,878$2.05
$10.00kBuy
George Adi MorChief Executive Officer2026-05-294,926$2.08
$10.25kBuy

1 of 1

CMMB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CMMB insiders and whales buy or sell their stock.

CMMB Shareholders

What type of owners hold Chemomab Therapeutics Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Access Industries Holdings LLC1.19%6,911,166$18.04MInsider
Gabriel Capital Management Ltd0.87%5,034,150$13.14MInsider
Orbimed Israel GP Ltd0.39%2,241,274$5.85MInsider
George Adi Mor0.19%1,091,698$2.85MInsider
Peter Thiel0.15%877,973$2.29MInsider
Dennison T. Veru0.07%396,540$1.03MInsider
Stephen P. Squinto0.01%47,938$125.12kInsider
Frank Haluska0.01%36,082$94.17kInsider
Neil Harris Cohen0.01%33,000$86.13kInsider
John Lawler0.00%20,000$52.20kInsider

1 of 3

CMMB vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CMMB0.00%2.89%Net BuyingNet Selling
ALLR0.01%16.02%Net Selling
LPCN0.04%90.51%Net Buying
LTRN0.02%53.50%Net Buying
PTN0.00%100.00%Net SellingNet Selling

Chemomab Therapeutics Stock Ownership FAQ

Who owns Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ: CMMB) is owned by 0.00% institutional shareholders, 2.89% Chemomab Therapeutics insiders, and 97.11% retail investors. Access Industries Holdings LLC is the largest individual Chemomab Therapeutics shareholder, owning 6.91M shares representing 1.19% of the company. Access Industries Holdings LLC's Chemomab Therapeutics shares are currently valued at $17.14M.

If you're new to stock investing, here's how to buy Chemomab Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.